FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
CO19 | Hypercoagulability in wild-type transthyretin amyloidosis: evidence from whole blood thromboelastometry A. Napolitano1, L. Spiezia1, C. Samà1, A. Benetti1, G. Sinigiani2, L. De Michieli2, A. Cipriani2, P. Simioni1 | 1First Chair of Internal Medicine, Department of Medicine, University Hospital of Padua; 2Department of Cardiothoracic and Vascular Sciences & Public Health, University Hospital of Padua, Italy
607PDF: 18 -
PO070 | INFECTIVE ENDOCARDITIS AND ISCHEMIC CEREBRAL EVENTS IN A PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND TRIPLE ANTIPHOSPHOLIPID POSITIVITY: THE ROLE OF ANTICOAGULATION IN PRIMARY PREVENTION T. Marrazzo1, M.P. Ursi2, R. Andini1, R. Albisinni3 | 1UOC Med Interna e dei Trapianti; 2UOC Mecau; 3UOC CCH generale, Osp. Monaldi AORN dei Colli, Napoli, Italy
58PDF: 25 -
PO55 | HISTORY OF CANCER IN PATIENTS WITH SEVERE HEREDITARY THROMBOPHILIA VERSUS NO THROMBOPHILIA: A SINGLE-CENTER COHORT OF PATIENTS WITH VENOUS THROMBOSIS A. Napolitano, E. Campello, C. Simion, G. Furlan, S. Gavasso, C. Bulato, C. Samà, S. Toffanin, B. Serena, L. Spiezia, P. Simioni | Internal Medicine 1 and Thrombotic and Hemorrhagic Diseases Unit, Department of Medicine, University of Padova, Italy
532PDF: 114 -
PO002 | VENOUS THROMBOEMBOLISM IN PATIENTS WITH FACTOR VII DEFICIENCY: A CASE SERIES AND REVIEW OF THE LITERATURE BM. Roccon1, MI. Tassoni1, G. Quintavalle1, F. Riccardi1, A. Matichecchia1, GF. Rivolta1, M. Lombardi3, R. Rossi2, A. Benegiamo2, A. Tagliaferri1, A. Coppola1 | 1SSD Centro Hub Emofilia e Malattie Emorragiche Congenite, Azienda Ospedaliero-Universitaria di Parma, Italy; 2Lab. di Coagulazione, UOC Diagnostica Ematochimica, Azienda Ospedaliero-Universitaria di Parma, Italy; 3Centro Emostasi, UOC Medicina Interna ad indirizzo angiologico e coagulativo, Azienda Ospedaliero-Universitaria di Parma, Italy
49PDF: 21 -
PO30 | LONG-TERM ANTICOAGULANT THERAPY AND PREVENTION OF RECURRENT VENOUS THROMBOEMBOLISM IN ADVANCED OVARIAN CANCER V. Bitsadze 1, A. Vorobev 1, J. Khizroeva 1, A. Solopova 1, M. Tretyakova 1, N. Gashimova 1, K. Grigoreva 1, A. Khisamieva 1, J. Gris 1|2, I. Elalamy1|3|4, G. Gerotziafas1|3|4, A. Makatsariya1 | 1Department of Obstetrics, Gynecology and Perinatal Medicine, N. F. Filatov Clinical Institute of Children’s Health, I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; 2Faculty of Pharmaceutical and Biological Sciences, Montpellier University, France; 3Department Hematology and Thrombosis Center, Medicine Sorbonne University, Paris, France; 4Hospital Tenon, Paris, France
480PDF: 100 -
PO56 | Safety of anticoagulant treatment in patients with splanchnic vein thrombosis and history of portal hypertension-related bleeding R. Talerico1, S. Pellegrino1, A. Plessier2, F.R. Ponziani3, A. Porfidia1, F. Landi1, A. Gasbarrini3, R. Pola1, F. Santopaolo3 | 1Department of Geriatric, Orthopedic, and Rheumatologic Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy; 2Université de Paris, AP-HP, C, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVE. Centre de recherche sur l’inflammation, Inserm, Paris, France; 3Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy
624PDF: 28 -
PO143 | GENDER DIFFERENCES IN COAGULATION PROFILE IN OBSTRUCTIVE CORONARY ARTERY DISEASE: PRELIMINARY RESULTS FROM AN ANGIOGRAPHICALLY CONTROLLED COHORT STUDY N. Osti1, G. Musuraca1, M. Spizzo2, P. Pattini2, G. Mango2, F. Ambrosani2, G. Poli3, C. Brocco1, C. Angheben1, M. Donini1, F. Presa2, M. Grusse4, P. Van Dreden4, A. Anesi1, G. Lippi3, M. Del Greco1, A. Castagna2, S. Friso2, A. Ferro1, N. Martinelli2 | 1Azienda Sanitaria Universitaria Integrata del Trentino, Trento, Italy; 2Dip. di Medicina, Università di Verona, Verona, Italy; 3Sez. di Biochimica Clinica, Università di Verona, Verona, Italy; 4Clinical Research, Diagnostica STAGO, Gennevillers, France
52PDF: 25 -
CO032 | VENOUS THROMBOEMBOLISM IN ACUTE IMMUNE MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA, A SINGLE-CENTER RETROSPECTIVE COHORT STUDY M. Zerbinati, E. Cosi, I. Bertozzi, G. Bogoni, A. Bertomoro, A. Galbiati, I. Cortella, L. Gianesello, D. Regazzo, S. Ferrari, P. Simioni | Department of Medicine, University of Padova, Italy
73PDF: 22 -
CO15 | Longitudinal coagulation profiling of individuals undergoing gender-affirming hormone therapy: the hyper-gender study A. Napolitano, E. Campello, A. Scala, C. Simion, C. Bulato, S. Gavasso, C. Samà, A. Benetti, S. Toffanin, G. Faggian, R. Scafa, A. Garolla, P. Simioni | First Chair of Internal Medicine, Department of Medicine, University Hospital of Padua; Unit of Andrology and Reproductive Medicine, Department of Medicine, University Hospital of Padua, Italy
686PDF: 22 -
PO068 | ANTIPHOSPHOLIPID ANTIBODIES IN PATIENTS WITH MULTIPLE SCLEROSIS AND MS-LIKE DISEASES: MS OR APS? M. Gagliardi, L. Capone, A. Ciampa | Centro Emostasi, AORN Moscati, Avellino, Italy
37PDF: 25 -
PO53 | PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF REGN7508CAT FOR PRIMARY PROPHYLAXIS OF CANCER-ASSOCIATED THROMBOSIS FOR PARTICIPANTS WITH SOLID TUMORS UNDERGOING CANCER TREATMENT (ROXI-CAT-I) J. Zwicker1, M. P. O’Brien2, M. Carrier3, J. Connors4, A. Falanga5, A. Manzano6, R. Mcbane7, Y.Y. Janjigian1, G. O’Kane8, M. Onisko2, J. Kaplan2, A.P. Kithcart2, D.E. Gutstein2, A. Khorana9, M. F. Walsh2 | 1Memorial Sloan Kettering Cancer Center, New York, USA; 2Regeneron Pharmaceuticals, Inc. , Tarrytown, NY, USA; 3University of Ottawa, Ottawa, ON, Canada; 4Harvard Medical School, Boston, MA, USA; 5Hospital Papa Giovanni XXIII, Bergamo, Italy; 6Hospital Universitario 12 de Octubre, Madrid, Spain; 7Mayo Clinic, Rochester, MN, USA; 8St. Vincent's University Hospital and School of Medicine, University College Dublin, Dublin, Ireland; 9James P. Wilmot Cancer Center and the Department of Medicine, University of Rochester, Rochester, NY, USA
529PDF: 125 -
PO21 | PSYCHOLOGICAL IMPACT OF CANCER-ASSOCIATED THROMBOSIS: DUAL BURDEN AND IMPLICATIONS FOR QUALITY OF LIFE AND INTEGRATED PATIENT-CENTERED CARE G. Gerotziafas1|4, Y. Mitrou5, M. Marchetti6, P. Las Casa1, A. Tafur7, V. Bitsadze3, J. Khizroeva3, D. Taizhanova8, D. Antic9, C. Frére10, A. Makatsariya3, L. Garderet1|11, A. Escargueil1, C. Ay12, N. Lomatkin13, Z. Tazi-Mezalek14, M. Sassi15, M. Catalano4|16, J. Gligorov1|17, J. Caprini18, P. Van Dreden1|19, J. Fareed2, A. Falanga6 | 1Sorbonne University, INSERM UMR_S_938, CRSA, Research Department "Cancer, Vessels, Biology and Therapeutics" (CaVITE), Research Group "Cancer-Angiogenesis-Thrombosis and Haemostasis," Thrombosis Center, University Institute of Cancerology (UIC), Saint Antoine University Hospital Assistance Publique Hôpitaux de Paris (AP-HP)Paris France; 2Center of Translational Research and Education, Department of Pathology and Laboratory Medicine, Loyola University Stritch School of Medicine, Maywood, Chicago, USA; 3Thrombosis Center, Department of Obstetrics, Gynecology and Perinatal Medicine, The I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; 4VAS-European Independent Foundation in Angiology/Vascular Medicine Milan Italy; 5Department of Phylosophy, National and Kapodistrian University of Athens, Greece; 6Department of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy. School of Medicine and Surgery, University of Milan Bicocca, Milan, Italy; 7Vascular Medicine, Endeavor Health, Evanston, IL, USA; Pritzker School of Medicine, University of Chicago, Chicago, IL 60637, USA; 8Department of Internal Diseases, Karaganda Medical University Non-Commercial Joint Stock Company, Karaganda, Kazakhstan; 9Clinic for Hematology, University Clinical Center of Serbia, Faculty of Medicine University of Belgrade Belgrade Serbia; 10Department of Hematology, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, INSERM UMRS-1166 Institute of Cardiometabolism and Nutrition, Paris, France; 11Clinical Haematology Department, Sorbonne Université, Pitié-Salpêtrière Hospital, APHP, Paris; 12Department of Internal Medicine I, Clinical Division of Haematology and Haemostaseology, Medical University of Vienna, Vienna, Austria; 13Cardiology Division, Central Clinical Hospital of Presidential Administration, Moscow, Russia; 14Department of Internal Medicine, Hématologie Clinique, Centre Hospitalo-Universitaire Ibn Sina, Université Mohammed V de Rabat, Rabat, Morocco; 15Hematology Laboratory of Maternity and Neonatal Center of Monastir, Faculty of Pharmacy of Monastir, Monastir, Tunisia; 16Inter-University Research Center on Vascular Diseases, University of Milan-L Sacco Hospital, Milan, Italy; 17Medical Oncology Department, Tenon Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne University, Paris, France; 18Vascular Surgery, Pritzker School of Medicine at the University of Chicago, Chicago, USA; 19Clinical Research, Diagnostica Stago, Gennevilliers, France
464PDF: 96 -
PO38 | Rates of hemorrhagic events and hemodialysis circuit thrombosis in patients with end-stage renal disease on hemodialytic treatment receiving a factor-XI inhibitor: a systematic review and meta-analysis D. Santagata, G. Barbui, M.P. Donadini, A. Squizzato | Department of Medicine and Surgery, Research Center on Thromboembolic Disorders and Antithrombotic Therapies, University of Insubria, Varese and Como, Italy
626PDF: 34 -
PO29 | CANADIAN INSIGHTS INTO THE MANAGEMENT OF BREAKTHROUGH THROMBOSIS S. Ramdani1, C. Séguin2 | 1Division of Hematology, Post-Graduate Medical Education Program, McGill University, Montreal; 2Division of Hematology, Department of Medicine, McGill University Health Center, Montreal, Canada
498PDF: 99
